In The News

Applied BioMath, LLC Awarded Grant by the National Institutes of Health for Antibody Drug Conjugate Platform Model

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced they have been awarded a grant for the development of a software platform called Antibody Drug Conjugate (ADC) Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualificati

Applied BioMath, LLC Provides Systems Pharmacology Model to Support Fibrinolytic Therapy for Refractory COVID-19 Acute Respiratory Distress Syndrome

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced that it is creating a systems pharmacology model to support ongoing research into the compassionate care use of tissue plasminogen activator (tPA) as treatment of respiratory distress for patients with A

SIAM Announces New 2020 Leadership

Helen Moore has been appointed Council at Society for Industrial and Applied Mathematics (SIAM).

Helen Moore, Director of Applied Mathematics at Applied BioMath, will use her position to proactively address challenges including decisions that need to be made about ethics issues, open access journal policies, declining journal subscriptions, and emerging platforms for communicating research results. Moore currently serves on SIAM's Council.

CEOCFO Magazine 2019 Interview with John M. Burke, PhD

In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO of Applied BioMath discusses how Applied BioMath is focused on growing its team of industry leaders to better meet the needs of their biotech and pharma customers using mathematical modeling to de-risk and accelerate drug development. "Our growth plays a role in our brand recognition. Several of our most recent hires, including Alison Betts and Helen Moore, from Pfizer and AstraZeneca, respectively, are leaders in our industry," said Dr. John M.

Applied BioMath, LLC Announces Participation at PBSS San Francisco Antibody Drug Conjugate Workshop

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation as a sponsor at the Pharmaceutical and Bioscience Society (PBSS) San Francisco Antibody Drug Conjugate (ADC) workshop being held Wednesday September 12, 2018 at 8:45 a.m. at the SF Bay Area: Foster City Crowne Plaza in San Francisco, CA.

Applied BioMath, LLC awarded grant by National Institute on Aging of the NIH for the development of a systems pharmacology model in Alzheimer's Disease and Dementia

Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that they have been awarded a grant for development of a quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia.

CEOCFO Magazine 2017 Interview with John M. Burke, PhD

In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO at Applied BioMath discusses how Applied BioMath is modernizing drug discovery, drug development, and clinical trials by applying quantitative systems pharmacology (QSP), mathematical modeling and machine learning techniques to drug research and development. "We help predict the failures much earlier - with the killer experiment, to help reduce late stage attrition rates," said Dr. John Burke. "This helps our collaborators prioritize their resources and their experiments."

Applied BioMath, LLC Welcomes Louis J. Latino, Jr. as Senior VP of Sales and Business Development

Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that Louis J. Latino, Jr. is joining its team as Senior Vice President of Business Development.  In this role, Lou will lead the Applied BioMath business development team and continue to develop the company's growth strategy in the biotechnology and pharmaceutical industry.

CEOCFO Magazine 2016 Interview with John M. Burke, PhD

In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO of Applied BioMath, discusses advanced mathematical dynamical systems pharmacology modeling and biology applications for drug discovery, development and clinical trials. "Our mathematical and biological rigor allows us to provide deep biological insights years earlier than they would surface in the clinic," said Dr. John M. Burke. "This is what sets us apart from previous efforts and also from competitors."

Dr. John Burke featured in CEO/CFO Magazine

Dr. John Burke, Co-Founder, President, and CEO of Applied BioMath, LLC was recently featuerd in CEO/CFO magazine. Lynn Fosse, Senior Editor of CEOCFO Magazine interviewed Dr. Burke to learn about how Applied BioMath is revolutionizing drug invention, why its technology is different than anything offered today, and examples where Applied BioMath helped optimize and accelerate drug development.

Read Dr. Burke's interview in CEO/CFO Magazine

Applied BioMath holds its full-day Science and Strategy Meeting

Applied BioMath's Scientific and Executive Leadership Teams recently spent the day at our Science and Strategy offsite. We reflected on 2015 projects, shared new science and technologies, and officially kicked off 2016. We are extremely proud of what we achieved in 2015, and we will work diligently to continue that momentum into and throughout 2016!

Applied BioMath welcomes Werner Meier to its Scientific Advisory Board

Applied BioMath (www.appliedbiomath.com) is thrilled to announce that Werner Meier is the newest member of its Scientific Advisory Board, which comprises pioneers and thought leaders in the mathematical modeling, biological engineering, biotechnology, and medical fields.   Werner joins key opinion leaders Douglas Lauffenburger, PhD, Dr. Joseph Loscalzo, MD, PhD, Bruce Tidor, PhD, and Michael Yaffe, MD, PhD. 

Applied BioMath announces annual Charitable Giving Program

At Applied BioMath, we believe strongly in giving back to our community.  One of our founding principles is to try and make the world a better place. Our products and services help our commercial partners make a better world through development of novel medicines, but our efforts shouldn’t stop there. Embedded in our corporate DNA is the commitment to help others less fortunate than ourselves. As a part of our Corporate Mission, Applied BioMath will partake in an annual Charitable Giving Program, donating a portion of our profits to charities selected by our team.

Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board

Applied BioMath is thrilled to announce that Dr.Joseph Loscalzo, MD, PhD is the newest member if its Scientific Advisory Board. Dr. Loscalzo is chair of the Department of Medicine and physician-in-chief at Brigham and Women's Hospital (BWH). A cardiovascular medicine specialist, he is also the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School (HMS).